A convergence of market forces will push life sciences employers to rethink their workforce strategies and reimagine how work ...
In the AI era, thriving life sciences organizations will differentiate themselves based on their ability to combine AIs power ...
For many families living with rare pediatric diseases, hope often arrives quietly — after years of uncertainty, missed diagnoses, and being told that treatment may never come in time. For Lindsey ...
Biopharma startups are conditioned to set their sights on blockbuster products, aiming out of the gate for assets that promise billions in annual sales across vast patient populations. The standard ...
Each January, the J.P. Morgan Healthcare Conference helps to set the biopharmaceutical industry agenda for the coming year, and more suits can be seen on the streets of San Francisco than during any ...
On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled ...
On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through ...
On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, following ...
Purifying therapeutic oligonucleotides demands methods that deliver high recovery, high purity, and reliable scalability. Gain insight into a complete workflow for isolating a native 21‑mer RNA oligo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results